Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1186/s12933-021-01254-1 http://scihub22266oqcxt.onion/10.1186/s12933-021-01254-1 33789663!8010779!33789663     free     free     free Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Cardiovasc+Diabetol 2021 ; 20 (1): 75 Nephropedia Template TP {{tp|p=33789663|t=2021. Report from the CVOT Summit 2020: new cardiovascular and renal outcomes |pdf=|usr=}}{{33789663}} gab.com Text Report from the CVOT Summit 2020: new cardiovascular and renal outcomes JO: Cardiovasc Diabetol http://www.kidney.de/pget.php?&tw=1&pmid=33789663 #FOAvip The 6th Cardiovascular Outcome Trial (CVOT) Summit "Cardiovascular and Renal Outcomes 2020" was the first to be held virtually on October 29-30, 2020. As in previous years, this summit served as reference meeting for in-depth discussions on the topic of recently completed and presented major outcome trials. This year, focus was placed on the outcomes of VERTIS-CV, EMPEROR-Reduced, DAPA-CKD, and FIDELIO-DKD. Trial implications for diabetes management and the impact on new treatment algorithms were highlighted for diabetologists, cardiologists, endocrinologists, nephrologists, and general practitioners. Discussion evolved from major outcome trials using SGLT-2 inhibitors for treatment and prevention of heart failure and chronic kidney disease in people with and without diabetes, to additional therapy options for chronic kidney disease with a novel mineralocorticoid receptor antagonist. Furthermore, challenges in diabetes management like COVID-19 and obesity, as well as novel treatment strategies and guidelines, were discussed.The 7th Cardiovascular Outcome Trial Summit will be held virtually on November, 18-19, 2021 ( http://www.cvot.org ). Twit Text FOAVip Report from the CVOT Summit 2020: new cardiovascular and renal outcomes ????Cardiovasc Diabetol http://www.kidney.de/pget.php?&tw=1&pmid=33789663 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33789663 #FOAvip English Wikipedia <ref>{{Cite pmid|33789663}}</ref> Report from the CVOT Summit 2020: new cardiovascular and renal outcomes #MMPMID33789663 Schnell O; Cos X; Cosentino F; Forst T; Giorgino F; Heersprink HJL; Kosiborod M; Wanner C; Standl E Cardiovasc Diabetol 2021[Mar]; 20 (1): 75 PMID33789663show ga The 6th Cardiovascular Outcome Trial (CVOT) Summit "Cardiovascular and Renal Outcomes 2020" was the first to be held virtually on October 29-30, 2020. As in previous years, this summit served as reference meeting for in-depth discussions on the topic of recently completed and presented major outcome trials. This year, focus was placed on the outcomes of VERTIS-CV, EMPEROR-Reduced, DAPA-CKD, and FIDELIO-DKD. Trial implications for diabetes management and the impact on new treatment algorithms were highlighted for diabetologists, cardiologists, endocrinologists, nephrologists, and general practitioners. Discussion evolved from major outcome trials using SGLT-2 inhibitors for treatment and prevention of heart failure and chronic kidney disease in people with and without diabetes, to additional therapy options for chronic kidney disease with a novel mineralocorticoid receptor antagonist. Furthermore, challenges in diabetes management like COVID-19 and obesity, as well as novel treatment strategies and guidelines, were discussed.The 7th Cardiovascular Outcome Trial Summit will be held virtually on November, 18-19, 2021 ( http://www.cvot.org ). |COVID-19/*epidemiology/therapy[MESH] |Cardiovascular Diseases/*epidemiology/therapy[MESH] |Clinical Trials as Topic/*methods[MESH] |Congresses as Topic/*trends[MESH] |Diabetes Mellitus, Type 2/epidemiology/therapy[MESH] |Humans[MESH] |Kidney/drug effects/physiology[MESH] |Mineralocorticoid Receptor Antagonists/administration & dosage[MESH] |Renal Insufficiency, Chronic/*epidemiology/therapy[MESH] |Research Report/*trends[MESH] |Sodium-Glucose Transporter 2 Inhibitors/administration & dosage[MESH]Report from the CVOT Summit 2020: new cardiovascular and renal outcome(epmc).pdf DeepDyve Pubget Overpricing